Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Umbilical Cord Tissue Allograft Defects for Ligamentous Injuries in Patients with Sinus Tarsitis: A Case Series

Version 1 : Received: 2 February 2024 / Approved: 12 February 2024 / Online: 13 February 2024 (08:01:19 CET)

How to cite: Parker, R.; Shou, J.; Woods, C.; Lambert, N.; Barrett, T. Umbilical Cord Tissue Allograft Defects for Ligamentous Injuries in Patients with Sinus Tarsitis: A Case Series. Preprints 2024, 2024020716. https://doi.org/10.20944/preprints202402.0716.v1 Parker, R.; Shou, J.; Woods, C.; Lambert, N.; Barrett, T. Umbilical Cord Tissue Allograft Defects for Ligamentous Injuries in Patients with Sinus Tarsitis: A Case Series. Preprints 2024, 2024020716. https://doi.org/10.20944/preprints202402.0716.v1

Abstract

Heel pain in the “funnel-shaped” space between the calcaneus, talus, and talocalcaneonavicular and subtalar joints may be representative of Sinus Tarsi syndrome. The pain is often characterized by a burning, numbness, or tingling sensation that can stem from strains and tears on the ligaments in that area. Injury treatment typically includes balance training, muscle exercises, bracing, foot orthosis, and non-steroidal anti-inflammatory drugs (NSAIDs). This study presents Wharton Jelly (WJ) tissue allografts as an alternative intervention for patients who fail standard-care treatments. WJ targets tissue defects, unlike other therapies, which aim to reduce swelling and symptomatic pain. This study includes five female patients who have previously failed standard-of-care treatment. Each received extracorporeal pulse-activated therapy (EPAT), WJ, laser therapy, and an orthotic. After an average of 80 days, the cohort had an overall 85.29% improvement in pain. The study's limitations include a small cohort size and a non-blinded design. Given the significant improvement in pain, WJ tissue allograft, combined with other techniques, presents an optimal patient care plan for tissue defects associated with Sinus Tarsi syndrome when standard-of-care treatments fail. These results provide evidence for a more extensive, randomized study to define dosage protocols further and confirm safety and efficacy.

Keywords

Sinus Tarsi syndrome; Heel pain; Extracorporeal pulse-activated therapy (EPAT); Standard-of-care treatments; Non-steroidal anti-inflammatory drugs (NSAIDs); Foot orthosis; Laser therapy

Subject

Medicine and Pharmacology, Orthopedics and Sports Medicine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.